A trial testing a nerve-sparing (NeuroSAFE) technique in radical prostatectomy may improve patient-reported outcomes.

The tissue damage and anatomical distortion caused by primary prostate cancer treatment are major challenges for surgeons performing salvage surgery.

My internal medicine physician, Bart, up and retired after 30+ years of taking care of me. I hated to see him go, since he ...

In the final moments of And Just Like That Season 3 Episode 6, Carrie Bradshaw (Sarah Jessica Parker) touchingly told her ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

The Motley Fool. DATE Tuesday, July 15, 2025 at 8:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

But I’ve been using AI tools for masturbation nearly every day. It’s just so easy to explore wacky and fun scenarios (specifically in the fantasy and sci-fi genres) that I’ve found it dividing my ...

Their first product, Illuccix, is a diagnostic imaging agent that allows PET scanners to light up the prostate cancer cells ...

Pulse deputy news editor Anna Colivicchi discusses the Government’s 10-year health plan with features assistant Maya Dhillon.

Johnson & Johnson MedTech has announced the U.S. Food and Drug Administration (FDA) approval of an update to the VARIPULSE ...